Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 218939, held by Ascent Pharms Inc. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 218939 (Carbidopa And Levodopa), held by Ascent Pharms Inc, was first approved by FDA on Jan 14, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 14, 2025 | Original application | Approved | None posted |
| Carbidopa And Levodopa10MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;250MG · tablet;oral | Carbidopa; Levodopa | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters